@article{1461547,
      recid = {1461547},
      author = {Shegokar, Ranjita. and Pathak, Yashwant.},
      title = {Tubercular drug delivery systems : advances in treatment  of infectious diseases /},
      publisher = {Springer,},
      address = {Cham :},
      pages = {1 online resource (334 p.)},
      year = {2023},
      note = {3.2.5 Supercritical Fluid-Based Method},
      abstract = {The disability-adjusted life year (DALY) is a generic  measure of health effect that can be used in  cost-effectiveness analysis as an alternative to the  quality-adjusted life year (QALY). Infectious diseases are  one of the major to cause significant losses of DALY and  QALY. Human infectious diseases are disorders that are  triggered by the microorganisms such as bacteria, fungi,  viruses, or parasites. The majority of such diseases are  contagious and create a public health menace. There are  several reasons why infectious diseases are deadly  diseases, and one of the primary reasons is the drug  resistance developed over time. Drug resistance-associated  mutations are linked to increasing drug efflux,  modifications of the drugs, or their targets. Every year,  new drugs are being approved by FDA to treat infectious  diseases. Nonetheless, the infectious diseases will  undoubtedly persist as permanent and main threats to  humanity now and in the future, primarily due to increased  longevity that almost always comes at a cost of impaired  immunity. A total of four books are covered under the  series of Infectious diseases. Malarial drug delivery  systems Tubercular drug delivery systems Viral drug  delivery systems Infectious disease drug delivery systems  The theme of the second book is Tuberculosis (TB). This  book addresses the recent trends in drug delivery for  treating TB using new formulation technologies, and the  mechanism how it can prevent or delay the drug resistance.  It covers current drug therapy and new drug targeting  approaches focusing on innovative trend-defining  technologies and drug delivery platforms. It is essential  to understand the relationship between host pathogens for  better treatment. Various novel and nano-formulations using  promising technologies are being explored to deliver TB  drugs via different administration routes at right  pathological site. This book addresses the gap between new  and old treatment TB modalities and how they are superior  in pharmacological performance when tested in in-vitro and  in-vivo. Audiences from a broad range of groups, from  researchers, academicians, and public health bodies to  regulatory experts, can benefit from the compiled  information to learn more about patient needs and current  research advances in the field of TB research.},
      url = {http://library.usi.edu/record/1461547},
      doi = {https://doi.org/10.1007/978-3-031-14100-3},
}